With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics.

Viking Therapeutics, Inc. (Viking), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that it has signed a broad ...

Yesterday, Viking signed a "broad manufacturing agreement" with Germany's CordenPharma to produce for it a "multi-ton annual supply" of Viking's own VK2735 GLP-1 weight-loss drug. VK2735 is still ...

Viking Ther­a­peu­tics has con­tract­ed CD­MO Cor­den­Phar­ma for a to­tal of $150 mil­lion to make bil­lions of clin­i­cal and com­mer­cial dos­es of its GLP-1/GIP re­cep­tor ...

Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC ...